

Supplemental Table 4. Comparison between relapsing and non-relapsing patients

	Non-Relapsing (N=47)	Relapsing (N=10)	P value
Male/Female	25/22	5/5	0.564
Age at onset, y, mean±SD	56.5±14.2	65.9±12.3	0.056
Symptom at diagnosis, n (%)			
Seizure	42 (89.4%)	9 (90%)	1
Memory deficit	34 (72.3%)	7 (70.0%)	0.579
Psychosis	14 (30.4%)	2 (20.0%)	0.406
Consciousness disorder	5 (10.6%)	3 (30.0%)	0.137
Speech disorder	3 (6.4%)	0 (0.0%)	1
Sleep disorder	3 (6.4%)	0 (0.0%)	1
Autonomic dysfunction	5 (10.6%)	0 (0.0%)	0.366
Limb weakness	4 (8.5%)	0 (0.0%)	1
Hyponatremia, n (%)	21 (44.7%)	4 (40%)	0.536
CSF findings, n (%)			
Cell count > 5 cells/uL	7 (15.6%)	2 (22.2%)	0.469
Protein > 0.45 g/L	12 (27.3%)	1 (11.1%)	0.287
Positive OB	4 (10.0%)	1 (12.5%)	0.616
LG11 antibody, n (%)			
CSF positive	26 (56.5%)	8 (80.0%)	0.154
Serum positive	47 (100%)	10 (100%)	1
EEG, n (%)			
Epileptic discharge	17 (53.1%)	1 (50%)	1
Slow wave	5 (15.6%)	1 (50%)	0.477
MRI, n (%)			
Normal	23 (49.0%)	7 (70.0%)	
Unilateral hippocampal lesion	12 (25.5%)	1 (10.0%)	
Bilateral hippocampal lesions	12 (25.5%)	2 (20.0%)	0.512
Tumor, n (%)	4 (9.1%)	2 (20%)	0.456
Treatment, n (%)			
Corticosteroid	37 (80.4%)	8 (80.0%)	0.637
IVIG	23 (50.0%)	5 (50.0%)	1
MMF	5 (10.9%)	0 (0.0%)	0.573
Antiepileptic drugs	40 (95.2%)	9 (90%)	0.481
Residual symptom, n (%)			
Cognition impairment	21 (44.7%)	7 (70.0%)	0.148
Epilepsy	6 (12.8%)	6 (60.0%)	0.002**
Personality change	9 (19.1%)	2 (20.0%)	1
BI upon admission, mean±SD	81.2±19.0	74±20.1	0.286
BI at discharge, mean±SD	85.2±17.6	72.5±24.0	0.057
mRS upon admission, median (IQR)	1 (1~3)	1 (1~3)	0.954
mRS at 12 months, median (IQR)	0 (0~1.25)	1 (1~1.75)	0.15

Abbreviations: SD, standard deviation; CSF, cerebrospinal fluid; OB, oligoclonal band; EEG, electroencephalography; MRI, magnetic resonance imaging; IVIG: intravenous immunoglobins; MMF, mycophenolate mofetil; BI, Barthel Index; mRS, modified Ranking scale; IQR, interquartile range. Bold value indicates statistical significance. *P<0.05; **P<0.01.